Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (original) (raw)
The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma
Ingemar Turesson
JAMA Oncology, 2015
View PDFchevron_right
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Dirk Larson
New England Journal of Medicine, 2002
View PDFchevron_right
Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients
Hannes Neuwirt
Oncotarget
View PDFchevron_right
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
Dirk Larson
The Lancet, 2010
View PDFchevron_right
Risk of monoclonal gammopathy of undetermined significance (MGUS) and …
martha linet
…
View PDFchevron_right
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
Theresia Akhlaghi
JAMA Oncology
View PDFchevron_right
A gene signature can predict risk of MGUS progressing to multiple myeloma
Clyde Bailey
Journal of Hematology & Oncology, 2023
View PDFchevron_right
Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All
Tarek Mouhieddine
Cancers
View PDFchevron_right
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
Mark Drayson
British Journal of Haematology, 2009
View PDFchevron_right
Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients
Dirk Larson
Mayo Clinic Proceedings, 2009
View PDFchevron_right
Survival of cancer patients with prior monoclonal gammopathy of undetermined significance
Marianne Severinsen
European Journal of Internal Medicine, 2010
View PDFchevron_right
Risk factors for monoclonal gammopathy of undetermined significance: a systematic review
maira avila
Annals of Hematology, 2021
View PDFchevron_right
Secondary Monoclonal Gammopathy of Undetermined Significance: A Sign Of Cure Or A Harbinger Of Relapse
Alia Saeed
Egyptian Journal of Hematology and Bone Marrow Transplantation
View PDFchevron_right
Prognostic Biomarkers in the Progression From MGUS to Multiple Myeloma: A Systematic Review
Charlotte Cosemans
Clinical Lymphoma Myeloma and Leukemia, 2018
View PDFchevron_right
Discovering the Meaning of Monoclonal Gammopathy of Undetermined Significance: Current Knowledge, Future Challenges
Carmela Palladino
Translational Medicine @ UniSa, 2014
View PDFchevron_right
Monoclonal Gammopathy of Undetermined Significance (MGUS): Indications for Pre-Diagnostic Testing, Subsequent Diagnoses, and Follow-up Practice
Aishwarya Ravindran
Blood, 2018
View PDFchevron_right
Abnormal serum free light chain ratio does not always indicate monoclonal gammopathy
Bogdan Ochrem
Polskie Archiwum Medycyny Wewnętrznej, 2015
View PDFchevron_right
The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance
S. Salah
Annals of Oncology, 2004
View PDFchevron_right
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
Dirk Larson
Blood, 2009
View PDFchevron_right
Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance
Rafael Fonseca
Journal of Clinical Oncology, 2005
View PDFchevron_right
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
P. Rodriguez-Otero
Blood Cancer Journal, 2019
View PDFchevron_right
Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden
Ola Landgren
Blood, 2009
View PDFchevron_right
Literature-based followup recommendations Part 7: Monoclonal gammopathy for the non-hematologist oncologist
Simron Singh, Dr. Malcolm Brigden
View PDFchevron_right
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study
Cecilie Blimark
Haematologica, 2009
View PDFchevron_right
Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients
Giuseppe G M Leone
British Journal of Haematology, 2013
View PDFchevron_right
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)
Antje Hoering
Blood, 2014
View PDFchevron_right
Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications
Angela Dispenzieri
Blood, 2010
View PDFchevron_right
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study
Ola Landgren
Blood, 2010
View PDFchevron_right
Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance
Ola Landgren
Haematologica, 2009
View PDFchevron_right
ROC defined serum globulin cutoff as a screening tool for monoclonal gammopathies
Carlos De La Cruz
Revista Medicina Universitaria
View PDFchevron_right
Long-term Follow-up of 241 Patients With Monoclonal Gammopathy of Undetermined Significance: The Original Mayo Clinic Series 25 Years Later
Dirk Larson
Mayo Clinic Proceedings, 2004
View PDFchevron_right
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network
Henk Lokhorst
Haematologica, 2014
View PDFchevron_right